
Medincell S.A (MEDCL) | Financial Analysis & Statements
Medincell S.A. | Mid-cap | Healthcare
Medincell S.A. | Mid-cap | Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Sep 2018Income Metrics
EPS (Diluted)
€0.00
Balance Sheet Metrics
Total Assets
90.5M
Total Liabilities
106.8M
Shareholders Equity
-16.4M
Cash Flow Metrics
Revenue & Profitability Trend
Medincell S.A Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 25.5M | 9.2M | 9.9M | 4.1M | 8.2M |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 25.5M | 9.2M | 9.9M | 4.1M | 8.2M |
Gross Margin % | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
Operating Expenses | |||||
Research & Development | 24.3M | 21.1M | 27.9M | 23.6M | 19.5M |
Selling, General & Administrative | 529.0K | 557.0K | 629.0K | - | - |
Other Operating Expenses | 3.8M | 3.7M | 2.7M | 2.8M | 2.5M |
Total Operating Expenses | 28.7M | 25.3M | 31.3M | 26.4M | 22.0M |
Operating Income | -10.8M | -21.0M | -24.0M | -23.8M | -15.6M |
Operating Margin % | -42.4% | -229.0% | -241.8% | -582.3% | -190.3% |
Non-Operating Items | |||||
Interest Income | 0 | 9.0K | 1.0K | 0 | 23.0K |
Interest Expense | 5.1M | 4.6M | 3.9M | 1.8M | 2.3M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | -18.3M | -25.0M | -32.0M | -24.8M | -19.0M |
Income Tax | 160.0K | 88.0K | 0 | 0 | 0 |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | -18.4M | -25.0M | -32.0M | -24.8M | -19.0M |
Net Margin % | -72.2% | -273.3% | -321.9% | -606.5% | -231.9% |
Key Metrics | |||||
EBITDA | -11.2M | -18.6M | -26.4M | -21.4M | -15.7M |
EPS (Basic) | - | €-0.86 | €-1.27 | €-1.00 | €-0.86 |
EPS (Diluted) | - | €-0.86 | €-1.27 | €-1.00 | €-0.86 |
Basic Shares Outstanding | - | 29071067 | 25188499 | 24865403 | 22044349 |
Diluted Shares Outstanding | - | 29071067 | 25188499 | 24865403 | 22044349 |
Income Statement Trend
Medincell S.A Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 59.0M | 19.5M | 6.5M | 24.6M | 47.1M |
Short-term Investments | 12.9M | - | 3.0K | 2.0M | 2.8M |
Accounts Receivable | 1.4M | 2.3M | 2.1M | 799.0K | 883.0K |
Inventory | - | - | 0 | 0 | 0 |
Other Current Assets | 100.0K | - | 55.0K | 22.0K | 16.0K |
Total Current Assets | 80.6M | 27.3M | 19.6M | 34.1M | 56.3M |
Non-Current Assets | |||||
Property, Plant & Equipment | 7.8M | 4.4M | 4.4M | 6.9M | 4.0M |
Goodwill | 2.6M | 2.5M | 1.9M | 1.7M | 1.5M |
Intangible Assets | 2.6M | 2.5M | 1.9M | 1.7M | 1.5M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 31.0K | 13.0K | 26.0K | 42.0K | 3.0K |
Total Non-Current Assets | 9.8M | 9.7M | 9.8M | 10.2M | 7.3M |
Total Assets | 90.5M | 36.9M | 29.3M | 44.3M | 63.6M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 4.0M | 1.8M | 4.2M | 3.0M | 3.0M |
Short-term Debt | 7.3M | 6.2M | 40.4M | 28.3M | 3.6M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 134.0K | 129.0K | 126.0K | 107.0K | 165.0K |
Total Current Liabilities | 29.9M | 16.5M | 57.0M | 38.2M | 13.6M |
Non-Current Liabilities | |||||
Long-term Debt | 51.5M | 52.8M | 14.3M | 19.1M | 39.8M |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | 13.7M | 494.0K | 2.0K | 2.0K | 4.0K |
Total Non-Current Liabilities | 76.9M | 61.3M | 14.6M | 19.4M | 40.9M |
Total Liabilities | 106.8M | 77.8M | 71.6M | 57.7M | 54.5M |
Equity | |||||
Common Stock | 331.0K | 291.0K | 253.0K | 251.0K | 247.0K |
Retained Earnings | -18.4M | -25.0M | -32.0M | -24.8M | -19.0M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | -16.4M | -40.8M | -42.3M | -13.4M | 9.1M |
Key Metrics | |||||
Total Debt | 58.8M | 59.0M | 54.7M | 47.5M | 43.3M |
Working Capital | 50.7M | 10.8M | -37.5M | -4.2M | 42.7M |
Balance Sheet Composition
Medincell S.A Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -18.4M | -25.0M | -32.0M | -24.8M | -19.0M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | 3.0M | 2.8M | 2.3M | 2.4M | 1.6M |
Working Capital Changes | 22.4M | 5.5M | -4.2M | -2.4M | 804.0K |
Operating Cash Flow | 14.1M | -12.6M | -24.9M | -23.0M | -13.4M |
Investing Activities | |||||
Capital Expenditures | -747.0K | -323.0K | -528.0K | -1.6M | -645.0K |
Acquisitions | - | - | - | - | - |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | -747.0K | -323.0K | -528.0K | -1.6M | -645.0K |
Financing Activities | |||||
Share Repurchases | - | -25.0K | - | -192.0K | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | 0 | 13.8M | 30.0M | 3.3M | 18.7M |
Debt Repayment | -4.1M | -8.8M | -24.1M | -2.3M | -9.3M |
Financing Cash Flow | 35.7M | 28.4M | 6.6M | 857.0K | 51.7M |
Free Cash Flow | 17.8M | -13.1M | -22.0M | -23.3M | -13.0M |
Net Change in Cash | 49.1M | 15.4M | -18.8M | -23.7M | 37.7M |
Cash Flow Trend
Medincell S.A Key Financial Ratios
Valuation Ratios
Forward P/E
88.40
Price to Sales
21.09
PEG Ratio
88.40
Profitability Ratios
Profit Margin
-66.50%
Operating Margin
-17.30%
Return on Equity
112.65%
Return on Assets
-10.56%
Financial Health
Current Ratio
2.70
Debt to Equity
-4.11
Beta
1.08
Per Share Data
EPS (TTM)
€-0.62
Book Value per Share
€-0.50
Revenue per Share
€0.94
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
medcl | 584.8M | - | - | 112.65% | -66.50% | -4.11 |
Abivax SA | 5.0B | -23.91 | -639.37 | -196.12% | 0.00% | -16.16 |
Valneva SE | 857.1M | 70.64 | 4.50 | -38.02% | -34.15% | 105.63 |
Inventiva S.A | 536.1M | -1.25 | -1.40 | 172.73% | 0.00% | -1.70 |
BNP Paribas Easy | 463.1M | 15.99 | - | -96.39% | -27.22% | 2.22 |
Nanobiotix | 360.4M | -5.10 | - | 103.70% | 0.00% | -0.77 |
Financial data is updated regularly. All figures are in the company's reporting currency.